Neurocrine Biosciences, Inc.San Diego, California, United States
Disclosure information not submitted.
SAT-465 - Long-Term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone and Improved Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric
Saturday, June 13, 20269:30 AM - 4:30 PM CT
SUN-465 - Long-Term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses and Improves Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric
Sunday, June 14, 20269:00 AM - 4:00 PM CT
ORF32-02 - Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog™ Registry
Sunday, June 14, 20261:50 PM - 1:55 PM CT
ORF32-05 - Characterization of Children and Adolescents with Classic CAH WHO Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont
Sunday, June 14, 20262:25 PM - 2:40 PM CT
MON-495 - Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog™ Registry
Monday, June 15, 20269:00 AM - 2:00 PM CT
.jpg)
.jpg)